Last reviewed · How we verify

PPD Development, LP — Portfolio Competitive Intelligence Brief

PPD Development, LP pipeline: 0 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ARCAGY/ GINECO GROUP · 1 shared drug class
  2. Eli Lilly and Company · 1 shared drug class
  3. Guangzhou Institute of Respiratory Disease · 1 shared drug class
  4. Hoffmann-La Roche · 1 shared drug class
  5. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 shared drug class
  6. Liaoning Cancer Hospital & Institute · 1 shared drug class
  7. Peking University Cancer Hospital & Institute · 1 shared drug class
  8. Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for PPD Development, LP:

Cite this brief

Drug Landscape (2026). PPD Development, LP — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ppd-development-lp. Accessed 2026-05-15.

Related